Related Experiment Videos

Species-specificity of pyrimethamine in the rodent bone marrow micronucleus test

T Ono1, T Sekiya, Y Takahashi

  • 1National Veterinary Assay Laboratory, Tokyo, Japan.

Mutation Research
|April 24, 1997
PubMed

Insights

Pyrimethamine, an antiprotozoal drug, is a clastogen in vitro but showed species-specific effects in vivo. Rat bone marrow micronucleus tests revealed significant induction of micronucleated polychromatic erythrocytes (MNPCEs), unlike in mice.

Area of Science:

  • Genotoxicity testing
  • In vivo cytogenetics
  • Drug safety evaluation

Background:

  • Pyrimethamine is an antiprotozoal agent with known in vitro clastogenic activity.
  • Previous mouse studies showed no significant induction of micronuclei.
  • In vitro cytogenetic studies indicated pyrimethamine induces chromosome aberrations.

Purpose of the Study:

  • To investigate the clastogenicity of pyrimethamine in the rat bone marrow micronucleus test.
  • To compare the in vivo genotoxic effects of pyrimethamine between mice and rats.
  • To evaluate the necessity of rat micronucleus tests for clastogen assessment.

Main Methods:

  • Administration of pyrimethamine via oral gavage to rats.
  • Dosing regimens included multiple doses (20-120 mg/kg/day) and single doses (80 and 160 mg/kg).
  • Analysis of micronucleated polychromatic erythrocytes (MNPCEs) in rat bone marrow.

Main Results:

  • A significant, dose-dependent increase in MNPCE frequency was observed in rats.
  • The highest dose resulted in an 80-fold increase in MNPCEs compared to controls.
  • Single doses of pyrimethamine also significantly induced MNPCEs in rats.

Conclusions:

  • Pyrimethamine exhibits species-specific genotoxic effects in rodent bone marrow micronucleus assays.
  • Rat bone marrow micronucleus tests are crucial for evaluating clastogens identified in vitro.
  • Combined mouse and rat micronucleus testing may be necessary for comprehensive genotoxicity assessment.

Related Concept Videos